Retatrutide Afira 40 mg / 3 ml - triple agonist of GLP-1, GIP and glucagon

Retatrutide - what is it and how does it work?

Retatrutide is one of the most promising molecules of the new generation, which is currently being studied for the treatment of obesity and related metabolic disorders.

Unlike drugs that affect only GLP-1, retatrutide simultaneously activates three receptors: GLP-1, GIP and glucagon receptor (GCGR). That is why it is called a triple agonist. Sometimes on the Internet you can find the name “GLP-3”, but this is not a scientific term.

For a person who has been struggling with excess weight for years, constant appetite, food cravings and weight regain after losing weight, the most interesting is the complex effect of this molecule on the mechanisms of weight regulation and energy metabolism.

How does retatrutide different from other weight control drugs?

Semaglutide works mainly through the GLP-1 receptor. Tirzepatide - through GLP-1 and GIP. Retatrutide combines effects on GLP-1 + GIP + glucagon receptors.

This triple action has led to great interest in the molecule in the field of obesity treatment.

In a randomized phase II study, the average weight loss after 48 weeks reached 24.2% in the 12 mg group, while in the placebo group it was 2.1%. The most common adverse reactions were gastrointestinal events, and their incidence was dose-dependent.

In 2026, the results of the phase III TRIUMPH-1 were available. According to Lilly, participants on a dose of 12 mg lost an average of 28.3% of their body weight over 80 weeks, and 45.3% of participants achieved a weight loss of at least 30%.

This makes retatrutide one of the most studied molecules of the new generation in the direction of obesity pharmacotherapy today.

What else is being studied?

The clinical program of retatrutide is not limited to the number on the scale. In Phase III, it was studied in people with obesity and cardiovascular disease, type 2 diabetes, osteoarthritis of the knee, and obstructive sleep apnea.

In TRIUMPH-2, participants with overweight/obese and type 2 diabetes reported a mean weight loss of up to 20.8% over 80 weeks and improvements in HbA1c.

Retatrutide Afira 40 mg / 3 ml

The presented format contains 40 mg of retatrutide in 3 ml in a pre-filled pen.

This is a concentrated format, so the calculation of the amount of active substance and any application requires special attention.

Important: Retatrutide remains an investigational molecule. Positive results in clinical trials do not mean automatic approval of a specific product or brand by regulatory authorities. The information on the page is for informational purposes only and does not replace a doctor's consultation.